INTRODUCTION
Diabetic retinopathy (DR) is a common, vision-limiting vascular complication of diabetes with a prevalence of approximately 35% [1, 2] . A visual complication manifesting in 6.8% of patients with DR is diabetic macular oedema (DMO), a chronic condition and the most common cause of DR-related vision-loss, particularly in patients with type 2 diabetes [2, 3] . 14-25% of patients diagnosed with diabetes appear to develop DMO within 10 years of the initial diagnosis [4] .
Given the association between DMO and vision loss, its early and effective management is critical. However, as a chronic and persistent visual complication that does not follow the natural disease course of DR, it is difficult to manage [3] . Historically, the standard of care was laser therapy, and this approach is still widely used. More recently, the preferred standard of care in patients with DMO has become anti-VEGF therapy [5] . This approach is supported by the outcomes from several large, prospective, randomized clinical trials demonstrating improvements in DMO and associated visual function [6] [7] [8] . However, a notable proportion of patients remain insufficiently responsive to anti-VEGF treatment in clinical practice, as shown by a cohort of patients (n = 190) in the RIDE and RISE trials (ClinicalTrials.gov identifiers:
NCT00473382 and NCT00473330, respectively), who crossed over from sham to ranibizumab treatment after two years. In this patient group, the improvement in VA after 1 year of therapy was notably less when compared with 1-year gain in VA in patients who initiated ranibizumab at the start of the study [mean 2.8 vs. 11.1 Early Treatment Diabetic Retinopathy (ETDRS) letter gain, respectively] [7, 8] suggesting that patients with a longer duration of DMO (chronic DMO) were less likely to achieve a response with ranibizumab.
Diabetic macular oedema is a multifactorial disease, involving the up-regulation of multiple inflammatory cytokines in addition to VEGF [9] . Consequently, corticosteroids, which have a broader-spectrum of activity, may represent an alternative therapeutic option for patients with chronic DMO. Data from the Fluocinolone Acetonide in Diabetic Macular Edema [FAME (ClinicaTrials.gov identifier. NCT00344968)] trials indicate efficacy of 0.2 lg/day FAc implant in DMO [17] . In Europe, 0.2 lg/day
FAc implant is approved for the treatment of vision impairment associated with chronic DMO considered insufficiently responsive to available therapies [10] . In the UK, the National with DMO were insufficiently responsive to ranibizumab based on these response criteria, and their patient records flagged accordingly.
Group 2: Patients Unresponsive to Macular Laser Therapy
The EPR audit tool was used to identify which patients with NSC-confirmed grade M1 maculopathy had received more than one macular laser treatment (Fig. 1, group 2 ). In addition, those patients assigned to group 1 during the EPR search, having received ranibizumab, were cross-checked and any duplicate patient entries deleted; therefore, all patients included in group 2 were ranibizumab naïve. Records for patients with non-DMO indications were excluded.
The selected patient records were exported and reviewed to identify pseudophakic patients with DMO unresponsive to macular laser Those patients with NSC-confirmed grade M1 maculopathy who were originally identified and who did not conform to the criteria specified for inclusion in group 1 or 2 were included in group 3 (excluding all patients with non-DMO indications; Fig. 1 ). These patients had CRT greater than 250 lm but less than 400 lm and so were considered unsuitable for ranibizumab treatment in the UK, based on NICE TA274 guidance (recommends ranibizumab only in patients with CRT [400 lm) [13] . Consequently, patient records were screened to identify those patients where macular laser therapy might not be optimal and anti-VEGF therapy is not recommended, but who might benefit from early intervention with 0.2 lg/day FAc implant to reduce CRT and manage DMO progression effectively. Of note, this patient group included some patients who were unsuitable for laser or ranibizumab therapy but who had received prior laser therapy. Consequently, such patients who had received two or more laser treatments were 'counted twice' as they were also included in group 2.
RESULTS
Overall, the EPR search identified 138 patients with DMO, whose demographic characteristics were broadly as anticipated (Table S1 in the supplementary material). The average patient age was 64 years [range 27-86 years; standard deviation (SD) ±13.1 years], and most patients were male (n = 85). The majority of patients had type 2 diabetes (n = 112). Of the 138 patients (264 eyes), 67 eyes were pseudophakic, 123 were phakic, and in the remaining 74 eyes the lens status was not documented (Fig. 1 ).
Group 1: Patients Insufficiently
Responsive to Ranibizumab Overall, 87 patients had received treatment with ranibizumab and were allocated to group 1 (Table S1) Table 2 presents the data on functional and anatomical visual measurements for each eye.
Based on the pre-specified criteria, 10/13 pseudophakic eyes were deemed to have failed macular laser therapy and thus were considered potential candidates for 0.2 lg/day FAc implant.
In these patients, the mean change in CRT and BCVA from baseline (referral) were ?8.2 lm (SD ±54.7 lm) and -13.1 letters (SD ±11.1 letters), respectively. Patients with unknown lens status were considered unsuitable for 0.2 lg/day FAc implant at this time, as their lens status was assumed to be phakic.
Group 3: Patients with Centre-Involving

DMO Unsuitable for Ranibizumab or Macular Laser Treatment
Overall, 40 eyes from 29 patients were allocated to group 3 (Table S1 ). In those patients (n = 23) who were pseudophakic or with unknown lens status, 11 eyes had previously received 1-3 laser treatments and 3 eyes reported co-pathologies ( insufficiently responsive and who might benefit from this treatment, a practical approach with broad applicability is required. This study Table 2 Prior laser therapy, co-pathologies, and CRT and BCVA at referral (baseline) and most recent measure (post-laser) in pseudophakic patients and patients with unknown lens status (e.g., may be pseudophakic) with diabetic macular oedema who had received more than one prior laser therapy Eye Pseudophakic/ order of a few days, compared with the long process (months) of prospective identification through the clinic. The anti-VEGF injection, ranibizumab, reaches therapeutic stability following treatment initiation with 3 consecutive monthly injections;
after this time, the majority of potential visual gain has been achieved [14, 15] . Consequently, for patients treated with ranibizumab in this study, success was evaluated in patients who had received C3 consecutive ranibizumab injections.
The criteria for treatment success were defined as a function of baseline VA. In patients with good baseline vision (C68 letters), but anatomical evidence for vision-threatening DMO (e.g., CRT C400 lm), the aim of treatment was to improve DMO (C20% reduction in CRT) or a gain of vision ([5 letters). However, in patients with worse vision (\68 letters), the aim of treatment was considered to be an improvement in DMO or maintenance of visual function (\5 letter gain). It is arguably of particular importance to identify treatment failure early in this latter group, as a retrospective analysis of the FAME studies demonstrated that visual outcomes were better in patients with chronic DMO with less deterioration in baseline BCVA whether they were treated with intermittent therapies or 0.2 lg/day FAc implant; however, patients in the latter group achieved notably better outcomes [16] .
A potentially overlooked cohort is those patients with DMO who have a CRT \400 lm.
It is assumed that, as they cannot access ranibizumab therapy in the UK due to a lack of evidence for cost-effectiveness in this patient group [13] , they will be treated with macular laser therapy. However, a proportion of patients exist for whom laser therapy would be potentially damaging, for example if the laser needs to be applied close to the centre of the retina. In addition, patients may have CRT \400 lm, but have received prior laser therapy that had been unsuccessful. This group of patients has a need for effective intervention to optimise outcomes and limit the damaging effects of progressive DMO, and thus represent a subgroup that may benefit from 0.2 lg/day FAc implant. Here, patients with CRT \400 lm but [250 lm who were not suitable for laser or ranibizumab therapy were reviewed to consider their suitability for 0.2 lg/day FAc implant, identifying a further 5 pseudophakic eyes whose records were flagged accordingly.
In [17] . This will require complete digital documentation, both facilitating and enhancing the value of an EPR audit system such as that described here.
However, more extensive digital patient records will not obviate the need for appropriate consideration of optimal search terms. Additionally, this study was performed within the context of the UK healthcare system using a specific EPR tool. However, the objectives of the study are relevant to other healthcare systems and the methodology is likely to be transferable to other technology platforms; the flexibility of EPR tools allows the use of locally derived criteria for the selection of specific patient populations.
CONCLUSIONS
To conclude, EPR audit offers a real-world and readily applicable methodology for optimizing treatment options in patients with DMO. 
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